Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of GnT-II gene down-regulated expression as liver cancer prognostic marker

A technology for prognosis and markers of liver cancer, applied in the field of molecular biology, can solve the problem of limited research on CD155 regulation

Pending Publication Date: 2021-02-19
PEOPLES HOSPITAL PEKING UNIV
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Despite the critical role of cellularly expressed CD155 within the tumor microenvironment of HCC, research on CD155 regulation is still limited

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of GnT-II gene down-regulated expression as liver cancer prognostic marker
  • Application of GnT-II gene down-regulated expression as liver cancer prognostic marker
  • Application of GnT-II gene down-regulated expression as liver cancer prognostic marker

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Example 1 Using the CRISRP human genome-wide coding gene knockout library to screen the coding gene GNT-II that regulates the expression of the inhibitory immune checkpoint molecule CD155

[0026] Although antibody drugs related to immune checkpoints have gradually begun to be used clinically, the regulatory mechanisms of these immune checkpoints are still less studied. Based on the CRISPR library, the present invention establishes a set of key gene technology for screening and regulating immune checkpoints. Through this technology, the key regulatory gene GNT-II of CD155 is screened, which provides a theoretical basis for the clinical application of CD155 monoclonal antibody drugs. The potential value as a prognostic indicator in liver cancer also brings more options for the development of anti-tumor drugs by blocking the TIGIT / CD155 axis with indirect monoclonal antibodies.

[0027] The specific method is as follows:

[0028] First, in 100% of CD155-expressing HCT116...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of GnT-II gene down-regulation expression as a liver cancer prognosis marker. A CRISRP human whole genome coding gene knockout library is used for screening a coding gene GNT-II for regulating expression of an inhibitory immune checkpoint molecule CD155, and it is found that expression of GNT-II in tumor tissue of a liver cancer patient is positively correlatedwith expression of CD155; and furthermore, the expression of the GNT-II is obviously related to the prognosis of the liver cancer patient, that is, the higher the expression of the GNT-II in the earlymale liver cancer patient is, the poorer the prognosis of the patient is. Therefore, the GNT-II has a certain potential application value as a prognosis index in liver cancer.

Description

technical field [0001] The invention relates to the field of molecular biology, and relates to the application of down-regulated expression of GnT-II gene as a liver cancer prognosis marker. Background technique [0002] Liver cancer is a common malignant tumor, and its case fatality rate ranks second among all malignant tumors, seriously threatening human life and health. Common treatment options for liver cancer, such as surgery, targeted therapy, transcatheter arterial chemoembolization and ablation, have very limited therapeutic effects on advanced liver cancer. In recent years, the emergence of immunotherapy has provided new options for the treatment of liver cancer. Emerging immunotherapy technologies such as cellular immunotherapy, cytokines, tumor vaccines, oncolytic viruses, and immune checkpoint inhibitors have also gradually advanced to clinical applications. However, the overall treatment response rate remains very limited. Immunotherapy represented by immune c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6851C12Q1/6886
CPCC12Q1/6851C12Q1/6886C12Q2600/118C12Q2600/158C12Q2531/113C12Q2545/113C12Q2561/113C12Q2563/107
Inventor 陈红松陈冬波陈谱邓康健廖维甲谢兴旺
Owner PEOPLES HOSPITAL PEKING UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com